Detection of neuroendocrine liver metastases with MnDPDP-enhanced MRI

Neuroendocrinology

Volumn 89, Issue 3, 2009, Pages 288-295

  Rockall, A G ^a,b   Planche, K ^a   Power, N ^a   Nowosinska, E ^a   Monson, J P ^a   Grossman, A B ^a   Reznek, R H ^a  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^b Dominion House ^*  (United Kingdom)

Author keywords

Mangafodipir trisodium (MnDPDP); MnDPDP enhanced MRI; Neuroendocrine liver metastases, detection; Neuroendocrine tumours

Indexed keywords

IOHEXOL; MANGAFODIPIR;

ADULT; AGED; ARTICLE; CANCER SIZE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; INTERMETHOD COMPARISON; LIVER METASTASIS; MALE; MULTIDETECTOR COMPUTED TOMOGRAPHY; NEUROENDOCRINE LIVER METASTASIS; NEUROENDOCRINE SYSTEM; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL;

ADULT; AGED; CONTRAST MEDIA; EDETIC ACID; FEMALE; HUMANS; IOHEXOL; LIVER NEOPLASMS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEUROENDOCRINE TUMORS; PYRIDOXAL PHOSPHATE; TOMOGRAPHY, X-RAY COMPUTED;

EID: 67349200709     PISSN: 00283835     EISSN: None     Source Type: Journal    
DOI: 10.1159/000176207     Document Type: Article

References (12)

1. Kaltsas GA, Besser GM, Grossman AB: The diagnosis and medical management of advanced neuroendocrine tumors. Endocr Rev 2004; 3: 458-511.
2. Woodard PK, Feldman JM, Paine SS, Baker ME: Midgut carcinoid tumors: CT findings and biochemical profiles. J Comput Assist Tomogr 1995; 19: 400-405.
3. Rockall AG, Britton KE, Grossman AB, Reznek RH: Neuroendocrine tumours; in Husband JE, Reznek RH (eds): Imaging in Oncology. London, Taylor & Francis, 2004, pp 789-814.
4. Paulson EK, McDermott VG, Keogan MT, Delong DM, Frederick MG, Nelson RC: Carcinoid metastases to the liver: role of triplephase helical CT. Radiology 1998; 206: 143-150.
5. Rummeny EJ, Marchal G: Liver imaging. Clinical applications and future perspectives. Acta Radiol 1997; 38: 626-630.
6. Federle M, Chezmar J, Rubin DL, Weinreb J, Freeny P, Schmiedl UP, et al: Efficacy and safety of mangafodipir trisodium (MnDPDP) injection for hepatic MRI in adults: results of the US Multicenter phase III clinical trials. Efficacy of early imaging. J Magn Reson Imaging 2000; 12: 689-701.
7. Heiken JP, Weyman PJ, Lee JK, Balfe DM, Picus D, Brunt EM, et al: Detection of focal hepatic masses: prospective evaluation with CT, delayed CT, CT during arterial portography, and MR imaging. Radiology 1989; 171: 47-51.
8. Lim KO, Stark DD, Leese PT, Pfefferbaum A, Rocklage SM, Quay SC: Hepatobiliary MR imaging: first human experience with MnDPDP. Radiology 1991; 178: 79-82.
9. Rummeny EJ, Torres CG, Kurdziel JC, Nilsen G, Op DB, Lundby B: MnDPDP for MR imaging of the liver. Results of an independent image evaluation of the European Phase III Studies. Acta Radiol 1997; 38: 638-642.
10. Bader TR, Semelka RC, Chiu VC, Armao DM, Woosley JT: MRI of carcinoid tumors: spectrum of appearances in the gastrointestinal tract and liver. J Magn Reson Imaging 2001; 14: 261-269.
11. Torres CG, Lundby B, Sterud AT, McGill S, Gordon PB, Bjerknes HS: MnDPDP for MR imaging of the liver. Results from the European Phase III Studies. Acta Radiol 1997; 38: 631-637.
12. Wang C: Mangafodipir trisodium (MnDPDP)- enhanced magnetic resonance imaging of the liver and pancreas. Acta Radiol 1998; 415(suppl):1-31.